Loading stock data…
$2.12-0.03 (-1.40%)
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Voyager Therapeutics, Inc. in the Healthcare sector is trading at $2.12 with a market capitalization of $197M. Wall Street consensus targets $14.89 (9 analysts), implying a +602.3% move over the next 12 months. The stock is currently near its 52-week low of $2.09, remaining 40.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.17M↑ | $2.59M↓ | $15.34M↑ | $13.37M↑ | $5.20M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.39M↑ | -$30.27M↓ | -$29.93M↑ | -$30.59M↑ | -$36.63M |
| Net Income | -$24.47M↑ | -$27.94M↓ | -$27.43M↑ | -$27.89M↑ | -$33.38M |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of...